JP2009510034A - 苦味活性成分の口腔内崩壊錠 - Google Patents
苦味活性成分の口腔内崩壊錠 Download PDFInfo
- Publication number
- JP2009510034A JP2009510034A JP2008532823A JP2008532823A JP2009510034A JP 2009510034 A JP2009510034 A JP 2009510034A JP 2008532823 A JP2008532823 A JP 2008532823A JP 2008532823 A JP2008532823 A JP 2008532823A JP 2009510034 A JP2009510034 A JP 2009510034A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- active ingredient
- cation exchange
- exchange resin
- coated granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 45
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 13
- 239000008187 granular material Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000003463 adsorbent Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 229920000642 polymer Polymers 0.000 claims abstract description 17
- 239000012608 weak cation exchange resin Substances 0.000 claims abstract description 17
- 239000007931 coated granule Substances 0.000 claims abstract description 16
- 230000002496 gastric effect Effects 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000002831 pharmacologic agent Substances 0.000 claims abstract description 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003729 cation exchange resin Substances 0.000 claims description 18
- 235000019640 taste Nutrition 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 15
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 229960002464 fluoxetine Drugs 0.000 claims description 15
- 230000000536 complexating effect Effects 0.000 claims description 9
- 206010006784 Burning sensation Diseases 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000008119 colloidal silica Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 6
- 229960001534 risperidone Drugs 0.000 claims description 6
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000007907 direct compression Methods 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 229920003121 gastrosoluble polymer Polymers 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 8
- 238000010668 complexation reaction Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000000873 masking effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 Aerosil Chemical compound 0.000 description 3
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940023913 cation exchange resins Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 3
- 229960000280 phenindione Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000805 composite resin Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(A)カルボン酸基(COO-)を含む弱カチオン交換樹脂により複合体化された、好ましくは酸付加塩の形態である、少なくとも1種のアミノ化薬理学的活性成分;及び
(B)活性成分/弱カチオン交換樹脂複合体の総重量に対して少なくとも15重量%の、少なくとも1種の親水性吸着剤;
の混合物を含む核により形成され、前記核は、胃溶解性ポリマーで被覆されている構成要素(A)及び(B)の混合物を含む被覆顆粒である。
(a)水性媒体中で、少なくとも1種のアミノ化薬理学的活性成分を、カルボキシル基(-COO-)を含む弱カチオン交換樹脂により複合体化する工程;
(b)複合体化のために用いた水分を少なくともまだいくらか含む、得られた活性成分/樹脂複合体を、前記活性成分/樹脂複合体の総重量に対して、少なくとも15重量%、好ましくは15〜50重量%の少なくとも1種の親水性吸着剤の存在下で顆粒化する工程;及び
(c)工程(b)において得られた顆粒を、少なくとも1種の胃溶解性ポリマーで被覆する工程;
を含む方法である。
−複合体化(方法の工程(a))−
100gのフルオキセチン塩酸塩と、200gのアンバーライト(AMBERLITE)IRP88樹脂(ジビニルベンゼンにより架橋されたポリメタクリル酸)を秤量し、次いで、ふるい分けをした(630μmのふるい)。800gの純水を攪拌し、次いで、フルオキセチンをそこに約5分間にわたってゆっくりと導入した。その混合物を約5分間攪拌し続けた後、アンバーライト(AMBERLITE)IRP88を約10分間にわたってゆっくりと加えた。その懸濁液の濃厚化が観察されたが、非常に急速に再液体化した。このようにして得られた混合物を、泡の形成を避けるために、その攪拌機が耐えられる最小の攪拌速度に制限するよう注意しながら2時間攪拌し続けた。
上記工程(a)で得られた混合物を、400rpmの速度で回転する遠心分離機(Rousselet RC20遠心分離機)のバスケット内に置く、ポリプロピレンろ過バッグ(多孔度:1〜5μm)に入れた。曇った、オフホワイト色の非常に細かい粒子の懸濁液であるろ液を回収し、残留物を含むろ過バックの中に再度入れた。このろ液の再循環は2度実施し、遠心分離機の速度を、各再循環工程の間に500〜1000rpmの速度に上げた。ろ液の最後の再循環工程の後、遠心分離機を数分間回転させた。1秒間に1滴の割合でろ液が回収されたならば、遠心を停止させた。このようにして最初に使用した水の約53%が除去された残留物を得た。このまだ湿っている残留物を、直接顆粒化工程に用いた。
約5分間にわたって、ふるい分けした48gの微結晶性セルロース(AVICEL PH101)と18gの沈降シリカ(SYLOID 244FP)を、最小の速度で回転するケンウッド「Chef」混合機に予め導入されていた、遠心分離したフルオキセチン/カチオン交換樹脂複合体に添加した。約5〜10分後、その混合物を残余湿度が約5%となるまで、流動層(GPCG 1)の中で乾燥した。得られた粉体は吸湿性であり、比較的細かい粒子から構成された。被覆する前にふるい分けした(500μm)。
165gのオイドラギット(EUDRAGIT)E100を1287gの96%エタノールに加え、それらをポリマーが完全に溶解するまで攪拌した。次いで、18gの沈降シリカ(SYLOID 244FP)を攪拌しながら加えた。
1回用量に20mgのフルオキセチン基剤を含む400mgの口腔内崩壊錠を、乾き圧縮により調製した。これらの錠剤は次の組成を有する。
パンチ:11mmポロ;
重量: 400mg;
硬度: 40N;
厚み: 約4mm;
製造率:10000〜15000錠/時間;及び
Fill-o-matic regime=10rpm。
80gのカチオン交換樹脂(INDION 204)を200gの純水中に分散させ、らせん状の攪拌機で10分間、塊のない懸濁液が得られるまで10分間攪拌した。20gのリスペリドンを添加し、その混合物を周囲温度で1時間攪拌した。この得られたリスペリドン/樹脂複合物を、278gのラクトース一水和物と22gのコロイドシリカ(AEROSIL 200)の混合物と一緒に、プラネタリー混合機の中で顆粒化した。この顆粒集合体は、1〜3%の湿分が得られるまで流動層内で乾燥した。40メッシュのふるいでふるい分けした後、その顆粒を、41.0gのEUDRAGIT EPO、2.88gのラウリル硫酸ナトリウム、6.15gのセバシン酸ジブチル、及び255gの純水から調製された水性被覆溶液で、ボトム-スプレー技法により、流動層の中で被覆した。得られた顆粒を同じ流動層の中で、5〜7%の湿分が得られるまで乾燥し、次いで、それらを35メッシュふるいを通してふるい分けをした。
Claims (10)
- (A)カルボン酸基(COO-)を含む弱カチオン交換樹脂により複合体化された、好ましくは酸付加塩の形態である、少なくとも1種のアミノ化薬理学的活性成分;及び
(B)活性成分/弱カチオン交換樹脂複合体の総重量に対して少なくとも15重量%の、少なくとも1種の親水性吸着剤;
の混合物を含む核により形成され、前記核は、胃溶解性ポリマーで被覆されている構成要素(A)及び(B)の混合物を含む被覆顆粒。 - 前記アミノ化薬理学的活性成分が、不快な味覚を有する及び/または体内への摂取の間に灼熱感を引き起こす活性成分であることを特徴とする、請求項1に記載の被覆顆粒。
- 前記親水性吸着剤(B)が、微結晶性セルロース及びコロイドシリカを含むことを特徴とする、請求項1または2に記載の被覆顆粒。
- 前記親水性吸着剤(B)が、活性成分/カチオン交換樹脂複合体の総重量に対して、15〜50重量%、好ましくは20〜40重量%の量で存在することを特徴とする、請求項1から3のいずれか一項に記載の被覆顆粒。
- 前記親水性吸着剤(B)が、活性成分/カチオン交換樹脂複合体の総重量に対して、少なくとも15重量%の微結晶性セルロースと少なくとも5重量%のコロイドシリカを含むことを特徴とする、請求項3または4に記載の被覆顆粒。
- 前記薬理学的活性成分が、フルオキセチン及びリスペリドン、好ましくはそれらの化合物の酸付加塩からなる群から選択されることを特徴とする、請求項1から5のいずれか一項に記載の被覆顆粒。
- 前記酸付加塩が塩酸塩であることを特徴とする、請求項6に記載の被覆顆粒。
- 前記弱カチオン交換樹脂が、架橋ポリメタクリル酸、好ましくはジビニルベンゼンで架橋されたポリメタクリル酸であることを特徴とする、請求項1から7のいずれか一項に記載の被覆顆粒。
- 請求項1から8のいずれか一項に記載の被覆顆粒と、崩壊剤、希釈剤、直接圧縮のための賦形剤、フロー剤、潤滑剤、甘味料及び香味料から選択される1種以上の補助剤とを含む口腔内崩壊錠。
- 請求項1から8のいずれか一項に記載の被覆顆粒を製造する方法であって、
(a)水性媒体中で、少なくとも1種のアミノ化薬理学的活性成分を、カルボキシル基(COO-)を含む弱カチオン交換樹脂により複合体化する工程;
(b)複合体化のために用いられた水分を少なくともいくらかまだ含む、得られた活性成分/樹脂複合体を、前記活性成分/樹脂複合体の総重量に対して少なくとも15重量%、好ましくは15〜50重量%の、少なくとも1種の親水性吸着剤の存在下で顆粒化する工程;及び
(c)工程(b)において得られた顆粒を少なくとも1種の胃溶解性ポリマーで被覆する工程;
を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0509900 | 2005-09-28 | ||
FR0509900A FR2891147B1 (fr) | 2005-09-28 | 2005-09-28 | Comprimes orodispersibles de principes actifs amers |
PCT/FR2006/002185 WO2007036632A1 (fr) | 2005-09-28 | 2006-09-25 | Comprimes orodispersibles de principes actifs amers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009510034A true JP2009510034A (ja) | 2009-03-12 |
JP5128482B2 JP5128482B2 (ja) | 2013-01-23 |
Family
ID=36753985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008532823A Active JP5128482B2 (ja) | 2005-09-28 | 2006-09-25 | 苦味活性成分の口腔内崩壊錠 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8865219B2 (ja) |
EP (1) | EP1928408B1 (ja) |
JP (1) | JP5128482B2 (ja) |
CN (1) | CN101277680B (ja) |
CA (1) | CA2624494C (ja) |
FR (1) | FR2891147B1 (ja) |
WO (1) | WO2007036632A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101879141B (zh) * | 2009-05-05 | 2013-07-17 | 烟台绿叶动物保健品有限公司 | 一种掩味替米考星胃溶颗粒制剂 |
US20120107381A1 (en) * | 2009-05-13 | 2012-05-03 | Relypsa, Inc. | Powder formulations of potassium-binding active agents |
EP2719377B1 (en) * | 2011-06-10 | 2018-04-18 | Nipro Corporation | Method for producing orodispersible tablets |
CN102429883A (zh) * | 2011-12-29 | 2012-05-02 | 天津市嵩锐医药科技有限公司 | 盐酸氟西汀口腔崩解药物组合物 |
EP2801349A1 (en) | 2013-05-06 | 2014-11-12 | Siegfried AG | Oral Pharmaceutical Formulation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0840884A (ja) * | 1994-07-20 | 1996-02-13 | Lilly Sa | フルオキセチン医薬製剤 |
JP2002534374A (ja) * | 1999-01-07 | 2002-10-15 | エラン コーポレーシヨン ピーエルシー | 多粒子経口用量形態 |
WO2004091585A1 (en) * | 2003-04-16 | 2004-10-28 | Synthon B.V. | Orally disintegrating tablets |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3594470A (en) * | 1968-02-19 | 1971-07-20 | Abbott Lab | Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin |
JPS6253997A (ja) * | 1985-09-03 | 1987-03-09 | Kowa Co | 新規なアミノ配糖体及びこれを含有する製剤 |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
AU741992B2 (en) * | 1998-03-06 | 2001-12-13 | Adare Pharmaceuticals S.R.L. | Fast disintegrating tablets |
DE60128215T2 (de) * | 2000-04-20 | 2008-01-10 | Novartis Ag | Beschichtungszusammensetzung zur geschmacksmaskierung |
ITMI20011338A1 (it) * | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio immediato del principio attivo |
US20050147663A1 (en) * | 2003-07-17 | 2005-07-07 | Mohan Mailatur S. | Method of treatment for improved bioavailability |
US20050250838A1 (en) * | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
-
2005
- 2005-09-28 FR FR0509900A patent/FR2891147B1/fr active Active
-
2006
- 2006-09-25 CA CA2624494A patent/CA2624494C/fr active Active
- 2006-09-25 EP EP06808201A patent/EP1928408B1/fr active Active
- 2006-09-25 JP JP2008532823A patent/JP5128482B2/ja active Active
- 2006-09-25 CN CN200680036246.8A patent/CN101277680B/zh active Active
- 2006-09-25 WO PCT/FR2006/002185 patent/WO2007036632A1/fr active Application Filing
- 2006-09-25 US US12/088,205 patent/US8865219B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0840884A (ja) * | 1994-07-20 | 1996-02-13 | Lilly Sa | フルオキセチン医薬製剤 |
JP2002534374A (ja) * | 1999-01-07 | 2002-10-15 | エラン コーポレーシヨン ピーエルシー | 多粒子経口用量形態 |
WO2004091585A1 (en) * | 2003-04-16 | 2004-10-28 | Synthon B.V. | Orally disintegrating tablets |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
Also Published As
Publication number | Publication date |
---|---|
CN101277680A (zh) | 2008-10-01 |
US20080248111A1 (en) | 2008-10-09 |
EP1928408B1 (fr) | 2012-10-31 |
FR2891147B1 (fr) | 2007-12-07 |
CN101277680B (zh) | 2015-06-24 |
FR2891147A1 (fr) | 2007-03-30 |
CA2624494A1 (fr) | 2007-04-05 |
EP1928408A1 (fr) | 2008-06-11 |
JP5128482B2 (ja) | 2013-01-23 |
CA2624494C (fr) | 2014-05-27 |
WO2007036632A1 (fr) | 2007-04-05 |
US8865219B2 (en) | 2014-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4749639B2 (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
RU2207121C2 (ru) | Фармацевтический препарат омепразола | |
JP5808670B2 (ja) | 弱塩基性薬物を含む組成物及び徐放性剤形 | |
US8202542B1 (en) | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings | |
JP2002534374A (ja) | 多粒子経口用量形態 | |
JP2001522874A (ja) | オメプラゾールの配合物 | |
JP2608183B2 (ja) | ピモベンダン経口投与製剤 | |
JP2002523443A (ja) | オメプラゾール製剤 | |
AU2003209673B2 (en) | Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof | |
JP5128482B2 (ja) | 苦味活性成分の口腔内崩壊錠 | |
JP2000191519A (ja) | 薬効成分の不快な官能的性質が隠蔽された速放性粒状物 | |
US20070092568A1 (en) | Galantamine compositions | |
JPH08198761A (ja) | ポリカルボフィルカルシウム含有製剤 | |
WO2002060448A1 (fr) | Composition medicinale | |
Khan | Oral Controlled Release Liquid Dosage Forms (Reconstitutable Powder) by Ion Exchange Resins | |
JPH07173065A (ja) | 速溶性の医療用アルギン酸ナトリウム造粒物およびその製造法 | |
JP2007015966A (ja) | 口腔内崩壊錠 | |
Alghabban et al. | Taste masking of prifinium bromide in orodispersible tablets | |
JP2004315424A (ja) | 苦味を低減した薬物含有速放性顆粒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121002 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121031 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5128482 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151109 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |